Modality
Small Molecule
MOA
EGFRi
Target
AuroraA
Pathway
Complement
CTCLNASH
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ May 2030
Phase 1Current
NCT04682997
2,509 pts·CTCL
2021-07→2030-05·Not yet recruiting
NCT03544935
1,559 pts·CTCL
2018-06→2026-02·Active
4,068 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-062mo agoPh2 Data· CTCL
2030-05-054.1y awayPh2 Data· CTCL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Active
P1/2
Not yet…
Catalysts
Ph2 Data
2026-02-06 · 2mo ago
CTCL
Ph2 Data
2030-05-05 · 4.1y away
CTCL
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04682997 | Phase 1/2 | CTCL | Not yet recr... | 2509 | DOR |
| NCT03544935 | Phase 1/2 | CTCL | Active | 1559 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET |